ERBB2 and breast carcinoma: This dual-receptor-targeted agent was specifically bound and internalized by breast cancer cells that expressed HER2, or EGFR, or both, and showed high absorbed radiation doses with 36–119 Gy in the cell nucleus treated with 177Lu-AuNPs-trastuzumab-panitumumab.